Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420786 | 0.91 | PARP1 (0.59) | PARP1ALDH1A1NR4A2MAOB | |
| SCHEMBL12420766 | 0.89 | NR4A2 (0.62) | PARP1ALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL12420780 | 0.87 | PARP1 (0.59) | PARP1ALDH1A1MAOB | |
| SCHEMBL12420779 | 0.87 | PARP1 (0.59) | PARP1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL12509138 | 0.87 | PARP1 (0.59) | PARP1ALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL12420602 | 0.83 | PARP1 (0.57) | PARP1ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL2195811 | 0.82 | PARP1 (0.56) | PARP1ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12509063 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL2336862 | 0.79 | SMN1; SMN2 (0.71) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL11085975 | 0.79 | ALDH1A1 (0.74) | PARP1ALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | PARP1 3006/4885ALDH1A1 259/4885SMN1; SMN2 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.